As the Ayurvedic healthcare sector faces increasing scrutiny, Cancertame aims to contribute through sustained research, manufacturing discipline & responsible innovation
Ishan Kaushal, Director
The growing interest in integrative healthcare has brought renewed attention to Ayurveda and its potential role in supporting patients with complex medical conditions. In cancer care, however, the challenge extends beyond traditional knowledge to establishing scientific evidence, maintaining product consistency and ensuring patient safety. As expectations around research transparency and regulatory compliance increase, organisations operating in this specialised segment must demonstrate a disciplined approach to formulation development and responsible healthcare practices.
Positioned within this evolving landscape is Cancertame, an Ayurvedic formulation developed through decades of herbal research associated with Sino Vedic Research Centre. Operating under Sino Vedic Healthcare Private Limited, with products marketed through the BharatVed brand, the organisation focuses on combining traditional medicinal knowledge with structured research, manufacturing quality and digital accessibility.
The organisation's journey began in 1983, rooted in the pioneering work of the late Dr. S.P. Kaushal, an MBBS qualified physician whose concerns about chemotherapy related side effects inspired him to investigate Ayurvedic and Chinese medicinal herbs and their supportive applications in cancer care. His son, Dr. Ishan Kaushal, who became involved in the clinic's operations early on and practiced alongside him as a doctor, subsequently carried this forty year research legacy forward. Having worked closely with his father, he brought a stronger emphasis on operational efficiency, pan India telemedicine, technology adoption and wider product accessibility.
A Research Legacy Built Over Decades
Cancertame's development reflects a long term research journey that began with the investigation of approximately 400 to 500 medicinal herbs. The research involved studying individual ingredients, examining different herbal combinations and documenting patient observations over extended periods.
A central consideration throughout the process was understanding the potential interactions between herbal formulations and conventional cancer treatments. Given the complexity of oncology care, the organisation recognised the importance of evaluating ingredients carefully and ensuring all preparations remain 100 percent pure botanical extracts, completely free from heavy metals and bhasmas.
The initial formulations, including Cancertame, Oncotame and Immunotone, were developed around 1993. Subsequent years were dedicated to further clinical evaluation, documentation and regulatory processes. These core oncology formulations officially received approvals between 2010 and 2014, enabling their commercial introduction.
This research oriented approach continues to influence the organisation's development priorities. Rather than treating formulation development as a one time exercise, Cancertame emphasises ongoing assessment, documentation and refinement as integral components of its operations.
Strengthening Quality and Manufacturing Consistency
For herbal formulation manufacturers, maintaining consistency across production batches remains a significant operational challenge. Variations in natural ingredients, complex processing requirements and the need for scalable production demand carefully controlled manufacturing practices.
“We address these challenges through standardised production procedures and collaborations with pharmaceutical manufacturing partners. Our operations strictly follow ISO and GMP certified manufacturing practices, with particular attention to pure botanical ingredient specifications, zero heavy metal policies and batch level quality assessments,” shares Dr. Ishan Kaushal, Director.
A typical production batch comprises approximately 2,000 to 3,000 units, from which representative samples are selected for testing. These assessments focus on maintaining ingredient consistency and ensuring that manufacturing specifications are followed across batches. The organisation also places importance on recording patient experiences and clinical outcomes through its associated healthcare professionals, using these observations to inform further research.
For its leadership, building stakeholder confidence requires more than commercial visibility. It involves maintaining transparent processes and ensuring that product related communication remains grounded in available evidence.
Expanding Accessibility through Digital Innovation
Alongside research and manufacturing, Cancertame has focused on overcoming the commercial limitations of conventional pharmaceutical distribution. Traditional intermediaries, according to its leadership, often demanded margins ranging from 40 to 60 percent, creating considerable pricing pressures.
To reduce dependence on these channels, the organisation adopted digital marketplaces, making Cancertame available through Amazon in 2020. Its broader online distribution strategy includes platforms such as Flipkart alongside direct online video consultations, supporting patient accessibility while limiting additional distribution costs.
As the Ayurvedic healthcare sector faces increasing scrutiny, Cancertame aims to contribute through sustained research, manufacturing discipline & responsible innovation
“Our technology adoption has since expanded beyond product availability. We have developed Cancer Talk, an AI powered healthcare information application for Android and iOS designed to respond to user queries and provide informational guidance based on medical literature, reference materials and historical case records,” speaks Dr. Ishan Kaushal.
At the time of the interview, the application was completing closed testing ahead of its public release. The initiative reflects the organisation's interest in improving access to verified healthcare information while recognising that AI generated responses require appropriate professional oversight.
Advancing Research and Responsible Integrative Care
Looking ahead, Sino Vedic Healthcare Private Limited is prioritising further evaluation of its research pipeline, including three next generation cancer formulations (Immunotone Plus, Oncotame Plus and Oncotame S) as well as expanding awareness for its ten approved chronic care formulations under the BharatVed brand, including Diabetame, Cardiovedic, Atherotame, Hepatovedic, Hormovedic, Neurovedic and Immunovedic. “Another priority involves enhancing Cancer Talk with a doctor verification feature, allowing users to request professional review of AI generated responses by qualified physicians. This is intended to strengthen information reliability and encourage informed healthcare decisions,” adds Dr. Ishan Kaushal.
Beyond product development, the organisation envisions greater collaboration between traditional and conventional medical disciplines, supported by rigorous scientific evaluation, transparent evidence and appropriate safeguards against treatment interactions.
As the Ayurvedic healthcare sector faces increasing scrutiny, Cancertame aims to contribute through sustained research, manufacturing discipline and responsible innovation. Its long term direction reflects a broader industry imperative: ensuring that traditional medicinal knowledge is examined through contemporary scientific standards, with patient safety and evidence based care remaining central to progress.